Highly purified eicosapentaenoic acid ethyl ester prevents development of steatosis and hepatic fibrosis in rats

Digestive Diseases and Sciences

Volumn 55, Issue 3, 2010, Pages 631-641

  Kajikawa, Satoshi ^a   Harada, Tsuyoshi ^a   Kawashima, Akiko ^a   Imada, Kazunori ^a   Mizuguchi, Kiyoshi ^a  

^a MOCHIDA PHARMACEUTICAL CO   (Japan)

Author keywords

Eicosapentaenoic acid; Fibrosis; Methionine and choline deficient diet; Nonalcoholic steatohepatitis; Steatosis; Transforming growth factor 1

Indexed keywords

8 ISOPROSTANE; CHOLINE; CONNECTIVE TISSUE GROWTH FACTOR; FERRITIN; HYDROXYPROLINE; ICOSAPENTAENOIC ACID ETHYL ESTER; MESSENGER RNA; METHIONINE; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; BIOLOGICAL MARKER; ICOSAPENTAENOIC ACID; ISOPROSTANE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FERRITIN BLOOD LEVEL; HISTOPATHOLOGY; LIVER FIBROSIS; LIVER LEVEL; LIVER NODULE; LIVER PARENCHYMA; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; ANIMAL; BLOOD; DISEASE COURSE; FATTY LIVER; GENETICS; LIVER; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY; WISTAR RAT;

ANIMALS; BIOLOGICAL MARKERS; CONNECTIVE TISSUE GROWTH FACTOR; DISEASE PROGRESSION; EICOSAPENTAENOIC ACID; FATTY LIVER; FERRITINS; ISOPROSTANES; LIVER; LIVER CIRRHOSIS; MALE; RATS; RATS, WISTAR; RECEPTORS, TUMOR NECROSIS FACTOR; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA1; TRIGLYCERIDES;

EID: 77949313797     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-009-1020-0     Document Type: Article

References (48)

1. M Duvnjak I Lerotić N Baršić V Tomašić L Virović Jukić V Velagić 2007 Pathogenesis and management issues for non-alcoholic fatty liver disease World J Gastroenterol 13 4539 4550 1:CAS:528:DC%2BD2sXhtFGksLfL 17729403 (Pubitemid 47455230)
2. YA Carpentier L Portois WJ Malaisse 2006 n-3 fatty acids and the metabolic syndrome Am J Clin Nutr 83 1499S 1504S 1:CAS:528:DC%2BD28XlvVOltro%3D 16841860 (Pubitemid 44713091)
3. KS Lee M Buck K Houglum M Chojkier 1995 Activation of hepatic stellate cells by TGFα and collagen type I is mediated by oxidative stress through c-myb expression J Clin Invest 96 2461 2468 10.1172/JCI118304 1:CAS:528:DyaK28XltF2gtg%3D%3D 7593635
4. A Uygun A Kadayifci AT Isik, et al. 2004 Metformin in the treatment of patients with non-alcoholic steatohepatitis Aliment Pharmacol Ther 19 537 544 10.1111/j.1365-2036.2004.01888.x 1:CAS:528:DC%2BD2cXjt1Gqsbg%3D 14987322 (Pubitemid 38387180)
5. R Belfort SA Harrison K Brown, et al. 2006 A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis N Engl J Med 355 2297 2307 10.1056/NEJMoa060326 1:CAS:528:DC%2BD28Xht1OrtrvI 17135584 (Pubitemid 44837778)
6. LA Adams P Angulo 2003 Vitamins E and C for the treatment of NASH: Duplication of results but lack of demonstration of efficacy Am J Gastroenterol 98 2348 2350 10.1016/j.amjgastroenterol.2003.08.001 1:CAS:528: DC%2BD3sXpt1SgurY%3D 14638333 (Pubitemid 37448741)
7. S Nakano T Nagasawa T Ijiro, et al. 2008 Bezafibrate prevents hepatic stellate cell activation and fibrogenesis in a murine steatohepatitis model, and suppresses fibrogenic response induced by transforming growth factor-β1 in a cultured stellate cell line Hepatol Res 38 1026 1039 10.1111/j.1872-034X. 2008.00363.x 1:CAS:528:DC%2BD1cXht12hs7fM 18513333
8. YB Lombardo AG Chicco 2006 Effects of dietary polyunsaturated n-3 fatty acids on dyslipidemia and insulin resistance in rodents and humans. A review J Nutr Biochem 17 1 13 10.1016/j.jnutbio.2005.08.002 1:CAS:528:DC%2BD2MXhtlajur7K 16214332 (Pubitemid 41774400)
9. L Spadaro O Magliocco D Spampinato, et al. 2008 Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease Dig Liver Dis 40 194 199 10.1016/j.dld.2007.10.003 1:CAS:528: DC%2BD1cXltFaju7c%3D 18054848 (Pubitemid 351181793)
10. T Kurihara M Akimoto H Ishiguro, et al. 1999 Effects of eicosapentaenoic acid on blood rheology in hyperlipidemic fatty liver patients Hemorheol Relat Res 2 1 7
11. M Yokoyama H Origasa M Matsuzaki, et al. 2007 Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis Lancet 369 1090 1098 10.1016/S0140-6736(07)60527-3 1:CAS:528:DC%2BD2sXjs1Ohtro%3D 17398308 (Pubitemid 46483662)
12. S Kajikawa T Harada A Kawashima K Imada K Mizuguchi 2009 Highly purified eicosapentaenoic acid prevents the progression of hepatic steatosis by repressing monounsaturated fatty acid synthesis in high-fat/high-sucrose diet-fed mice Prostaglandins Leukot Essent Fatty Acids 80 229 238 10.1016/j.plefa.2009.02.004 1:CAS:528:DC%2BD1MXmtVKnt7g%3D 19328666
13. SD Clarke 2001 Nonalcoholic steatosis and steatohepatitis. I. Molecular mechanism for polyunsaturated fatty acid regulation of gene transcription Am J Physiol Gastrointest Liver Physiol 281 G865 869 1:CAS:528:DC%2BD3MXnsFSksL8%3D 11557505
14. A Demoz N Willumsen RK Berge 1992 Eicosapentaenoic acid at hypotriglyceridemic dose enhances the hepatic antioxidant defense in mice Lipids 27 968 971 10.1007/BF02535573 1:CAS:528:DyaK3sXlt1ahtg%3D%3D 1487958 (Pubitemid 23008125)
15. S Kajikawa T Harada A Kawashima K Imada K Mizuguchi 2009 Suppression of hepatic fat accumulation by highly purified eicosapentaenoic acid prevents the progression of d-galactosamine-induced hepatitis in mice fed with a high-fat/high-sucrose diet Biochim Biophys Acta 1791 281 288 1:CAS:528:DC%2BD1MXjsVOisr0%3D 19416647
16. Y Zhao S Joshi-Barve S Barve LH Chen 2004 Eicosapentaenoic acid prevents LPS-induced TNF-α expression by preventing NF-κB activation J Am Coll Nutr 23 71 78 1:CAS:528:DC%2BD2cXitFSlsb4%3D 14963056 (Pubitemid 38200837)
17. S Sierra F Lara-Villoslada M Comalada M Olivares J Xaus 2008 Dietary eicosapentaenoic acid and docosahexaenoic acid equally incorporate as decosahexaenoic acid but differ in inflammatory effects Nutrition 24 245 254 10.1016/j.nut.2007.11.005 1:CAS:528:DC%2BD1cXhslGju74%3D 18312787 (Pubitemid 351179962)
18. MD Weltman GC Farrell C Liddle 1996 Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation Gastroenterology 111 1645 1653 10.1016/S0016-5085(96)70028-8 1:CAS:528:DyaK2sXisVWisQ%3D%3D 8942745 (Pubitemid 26404230)
19. S Takeo Y Nasa K Tanonaka, et al. 1998 Effects of long-term treatment with eicosapentaenoic acid on the heart subjected to ischemia/reperfusion and hypoxia/reoxygenation in rats Mol Cell Biochem 188 199 208 10.1023/A: 1006811009809 1:CAS:528:DyaK1cXns1Omu7w%3D 9823025 (Pubitemid 28493332)
20. H Yamada M Yoshida Y Nakano, et al. 2008 In vivo and in vitro inhibition of monocyte adhesion to endothelial cells and endothelial adhesion molecules by eicosapentaenoic acid Arterioscler Thromb Vasc Biol 28 2173 2179 10.1161/ATVBAHA.108.171736 1:CAS:528:DC%2BD1cXhtlKrtrzL 18948636
21. J Folch M Lees GH Sloane Stanley 1957 A simple method for the isolation and purification of total lipides from animal tissues J Biol Chem 226 497 509 1:STN:280:DyaG2s%2FnsFCjtw%3D%3D 13428781
22. JF Woessner Jr 1961 The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid Arch Biochem Biophys 93 440 447 10.1016/0003-9861(61)90291-0 1:CAS:528:DyaF3MXht1Ghu7c%3D 13786180
23. H Yoshiji S Kuriyama J Yoshii, et al. 2001 Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats Hepatology 34 745 750 1:CAS:528:DC%2BD3MXns1Kisrs%3D 11584371 (Pubitemid 32927999)
24. S Tsukada CJ Parsons RA Rippe 2006 Mechanisms of liver fibrosis Clin Chim Acta 364 33 60 10.1016/j.cca.2005.06.014 1:CAS:528:DC%2BD28XmslWhsg%3D%3D 16139830 (Pubitemid 43120627)
25. JW Haukeland JK Damås Z Konopski, et al. 2006 Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2 J Hepatol 44 1167 1174 10.1016/j.jhep.2006.02.011 1:CAS:528: DC%2BD28XksVaitr8%3D 16618517
26. Y Sumida T Nakashima T Yoh, et al. 2003 Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease J Hepatol 38 32 38 10.1016/S0168-8278(02)00331-8 1:CAS:528:DC%2BD38XptlSqt7k%3D 12480557 (Pubitemid 36078521)
27. K Tokushige E Hashimoto N Tsuchiya H Kaneda M Taniai K Shiratori 2005 Clinical significance of soluble TNF receptor in Japanese patients with non-alcoholic steatohepatitis Alcohol Clin Exp Res 29 298S 303S 1:CAS:528:DC%2BD28Xms1eh 16385240 (Pubitemid 43053687)
28. L Shapiro BD Clark SF Orencole DD Poutsiaka EV Granowitz CA Dinarello 1993 Detection of tumor necrosis factor soluble receptor p55 in blood samples from healthy and endotoxemic humans J Infect Dis 167 1344 1350 1:CAS:528:DyaK3sXmtVWgs7o%3D 8388902 (Pubitemid 23146182)
29. J George N Pera N Phung I Leclercq J Yun Hou G Farrell 2003 Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis J Hepatol 39 756 764 10.1016/S0168-8278(03)00376-3 1:CAS:528:DC%2BD3sXotVertrk%3D 14568258 (Pubitemid 37372185)
30. R Veteläinen A van Vliet TM van Gulik 2007 Essential pathogenic and metabolic differences in steatosis induced by choline or methione-choline deficient diets in a rat model J Gastroenterol Hepatol 22 1526 1533 10.1111/j.1440-1746.2006.04701.x 17716355 (Pubitemid 47274573)
31. JI Kennedy Jr DB Chandler JD Fulmer MB Wert WE Grizzle 1989 Dietary fish oil inhibits bleomycin-induced pulmonary fibrosis in the rat Exp Lung Res 15 315 329 10.3109/01902148909087861 1:CAS:528:DyaL1MXkt1amtr4%3D 2468480 (Pubitemid 19097749)
32. R Bataller DA Brenner 2005 Liver fibrosis J Clin Invest 115 209 218 1:CAS:528:DC%2BD2MXhtFyjs70%3D 15690074 (Pubitemid 40385459)
33. D Richard K Kefi U Barbe P Bausero F Visioli 2008 Polyunsaturated fatty acids as antioxidants Pharmacol Res 57 451 455 10.1016/j.phrs.2008.05.002 1:CAS:528:DC%2BD1cXoslWmsb8%3D 18583147
34. TC Schreuder BJ Verwer CM van Nieuwkerk CJ Mulder 2008 Nonalcoholic fatty liver disease: An overview of current insights in pathogenesis, diagnosis and treatment World J Gastroenterol 14 2474 2486 10.3748/wjg.14.2474 1:CAS:528:DC%2BD1cXptlWgs7s%3D 18442193 (Pubitemid 352037734)
35. K Begriche A Igoudjil D Pessayre B Fromenty 2006 Mitochondrial dysfunction in NASH: Causes, consequences and possible means to prevent it Mitochondrion 6 1 28 10.1016/j.mito.2005.10.004 1:CAS:528:DC%2BD28XhsFyru7k%3D 16406828 (Pubitemid 43250588)
36. I Kovalszky P Nagy B Szende, et al. 1998 Experimental and human liver fibrogenesis Scand J Gastroenterol Suppl 228 51 55 1:STN:280: DyaK1M%2FotlSjsA%3D%3D 9867113 (Pubitemid 28551891)
37. M Arias S Sauer-Lehnen J Treptau, et al. 2003 Adenoviral expression of a transforming growth factor-β1 antisense mRNA is effective in preventing liver fibrosis in bile-duct ligated rats BMC Gastroenterol 3 29 10.1186/1471-230X-3-29 14565855 (Pubitemid 38671514)
38. T Nakamura R Sakata T Ueno M Sata H Ueno 2000 Inhibition of transforming growth factor β prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats Hepatology 32 247 255 10.1053/jhep.2000.9109 1:CAS:528:DC%2BD3cXlvVyjt74%3D 10915731 (Pubitemid 30614657)
39. M Nakayama N Fukuda Y Watanabe, et al. 1999 Low dose of eicosapentaenoic acid inhibits the exaggerated growth of vascular smooth muscle cells from spontaneously hypertensive rats through suppression of transforming growth factor-β J Hypertens 17 1421 1430 10.1097/00004872-199917100-00009 1:CAS:528:DyaK1MXnsVSjur8%3D 10526902 (Pubitemid 29509487)
40. y/Ta mice: Involvement of anti-inflammation and antioxidative stress Metabolism 55 1590 1598 10.1016/j.metabol.2006.07.019 1:CAS:528:DC%2BD28Xht1Kns77L 17142129 (Pubitemid 44827124)
41. B Desvergne W Wahli 1999 Peroxisome proliferator-activated receptors: Nuclear control of metabolism Endocr Rev 20 649 688 10.1210/er.20.5.649 1:CAS:528:DyaK1MXmvFalsLo%3D 10529898 (Pubitemid 30650602)
42. C Chambrier JP Bastard J Rieusset, et al. 2002 Eicosapentaenoic acid induces mRNA expression of peroxisome proliferator-activated receptor γ Obes Res 10 518 525 10.1038/oby.2002.70 1:CAS:528:DC%2BD38XmsVWmsrs%3D 12055328 (Pubitemid 135686644)
43. A Kawashima T Harada K Imada T Yano K Mizuguchi 2008 Eicosapentaenoic acid inhibits interleukin-6 production in interleukin-1β-stimulated C6 glioma cells through peroxisome proliferator-activated receptor-gamma Prostaglandins Leukot Essent Fatty Acids 1-2 59 65 10.1016/j.plefa.2008.07.002
44. YM Nan N Fu WJ Wu, et al. 2009 Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice Scand J Gastroenterol 44 358 365 10.1080/00365520802530861 1:CAS:528:DC%2BD1MXit1eqtbk%3D 18991162
45. A Galli DW Crabb E Ceni, et al. 2002 Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro Gastroenterology 122 1924 1940 10.1053/gast.2002.33666 1:CAS:528:DC%2BD38Xlt12gsLw%3D 12055599 (Pubitemid 34651436)
46. R Hui M Robillard P Falardeau 1992 Inhibition of vasopressin-induced formation of diradylglycerols in vascular smooth muscle cells by incorporation of eicosapentaenoic acid in membrane phospholipids J Hypertens 10 1145 1153 10.1097/00004872-199210000-00006 1:CAS:528:DyaK3sXhtFOjtLY%3D 1334995
47. W Yu NR Murray C Weems, et al. 2003 Role of cyclooxygenase 2 in protein kinase C βII-mediated colon carcinogenesis J Biol Chem 278 11167 11174 10.1074/jbc.M211424200 1:CAS:528:DC%2BD3sXit1KgsLw%3D 12480928 (Pubitemid 36792671)
48. N Tanaka K Sano A Horiuchi E Tanaka K Kiyosawa T Aoyama 2008 Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis J Clin Gastroenterol 42 413 418 10.1097/MCG.0b013e31815591aa 1:CAS:528: DC%2BD1cXjsFWltbk%3D 18277895 (Pubitemid 351450629)